Mar 5
TriSalus Life Sciences reaffirms $60M–$62M revenue guidance for 2026 while expanding PEDD portfolio
Synthesized from 1 source
Sources (1)
Bias Scale:
LeftCenterRight
Seeking AlphaMar 5, 2026, 11:26 PM
TriSalus Life Sciences reaffirms $60M–$62M revenue guidance for 2026 while expanding PEDD portfolio60Trust
Comments
No comments yet. Be the first!